Article info

Download PDFPDF

Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA)

Authors

  1. Correspondence to Dr Paul Emery; p.emery{at}leeds.ac.uk
View Full Text

Citation

Emery P, Burmester GR, Naredo E, et al
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA)

Publication history

  • Received August 4, 2017
  • Revised December 5, 2017
  • Accepted December 7, 2017
  • First published February 28, 2018.
Online issue publication 
February 28, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.